Neoplasms Clinical Trial
Official title:
Multi-site Evaluation of a Video Game for Adolescents and Young Adults With Cancer
The purpose of this study is to determine the effects of playing the interactive video game, Re-Mission, on patient outcomes, including adherence to medical treatment regimes, self-care behaviors, quality of life, stress, communication, control, and knowledge.
POPULATION: Approximately 340 patients will be enrolled in this study. Patients will be 13
to 29 years of age with any cancer (original diagnosis or relapse), currently receiving
treatment and expected to be on treatment for at least 4 - 6 months following Baseline
assessment, and able to communicate effectively in English, Spanish, or French.
Approximately 170 patients will be enrolled in each of the two treatment groups. Each group
will receive either the "Re-Mission" video game and a popular interactive video game, or
just the popular interactive video game.
DESIGN: This is a multi-center, randomized trial, with patients randomized to one of two
groups. One group (50% of patients) will receive the active intervention, which is the
psycho-educational video game module called Re-Mission and a popular video game (hereafter
"RE-MISSION") and another group (50 % of patients) will be in a game control group and
receive a popular video game only (hereafter "GAME CONTROL. The games in the RE-MISSION and
GAME CONTROL groups are delivered on identical mini, personal computers (hereafter
"Mini-PC").
INTERVENTION: Each patient in the RE-MISSION group will be asked to play "Re-Mission" along
with the popular video game for at least one hour a week for a period of ten to fourteen
weeks. "Re-Mission" presents a 3-D environment in which the player can manipulate a humanoid
character inside the virtual body of a patient with cancer. Game-play consists of guiding
the character to destroy cancer cells and other "enemies" in the body (e.g., bacteria) while
avoiding injury or weakness. During the process of playing the game and guiding the
character through a series of missions, the player learns about chemotherapy and other
medical treatments, health-promoting self-care behaviors, infections, and pain management.
In addition, the game has also been designed to facilitate the patient's ability to share
knowledge and concerns with others.
DURATION OF STUDY: 9 -12 months
;
Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT03826043 -
THrombo-Embolic Event in Onco-hematology
|
N/A | |
| Terminated |
NCT03166631 -
A Trial to Find the Safe Dose for BI 891065 Alone and in Combination With BI 754091 in Patients With Incurable Tumours or Tumours That Have Spread
|
Phase 1 | |
| Completed |
NCT01938846 -
BI 860585 Dose Escalation Single Agent and in Combination With Exemestane or With Paclitaxel in Patients With Various Advanced and/or Metastatic Solid Tumors
|
Phase 1 | |
| Recruiting |
NCT06058312 -
Individual Food Preferences for the Mediterranean Diet in Cancer Patients
|
N/A | |
| Completed |
NCT03308942 -
Effects of Single Agent Niraparib and Niraparib Plus Programmed Cell Death-1 (PD-1) Inhibitors in Non-Small Cell Lung Cancer Participants
|
Phase 2 | |
| Recruiting |
NCT06018311 -
Exercising Together for Hispanic Prostate Cancer Survivor-Caregiver Dyads
|
N/A | |
| Withdrawn |
NCT05431439 -
Omics of Cancer: OncoGenomics
|
||
| Completed |
NCT01343043 -
A Pilot Study of Genetically Engineered NY-ESO-1 Specific NY-ESO-1ᶜ²⁵⁹T in HLA-A2+ Patients With Synovial Sarcoma
|
Phase 1 | |
| Completed |
NCT01938638 -
Open Label Phase I Dose Escalation Study With BAY1143572 in Patients With Advanced Cancer
|
Phase 1 | |
| Recruiting |
NCT05514444 -
Study of MK-4464 as Monotherapy and in Combination With Pembrolizumab in Participants With Advanced/Metastatic Solid Tumors (MK-4464-001)
|
Phase 1 | |
| Recruiting |
NCT02292641 -
Beyond TME Origins
|
N/A | |
| Terminated |
NCT00954512 -
Study of Robatumumab (SCH 717454, MK-7454) in Combination With Different Treatment Regimens in Participants With Advanced Solid Tumors (P04722, MK-7454-004)
|
Phase 1/Phase 2 | |
| Recruiting |
NCT04958239 -
A Study to Test Different Doses of BI 765179 Alone and in Combination With Ezabenlimab in Patients With Advanced Cancer (Solid Tumors)
|
Phase 1 | |
| Recruiting |
NCT04627376 -
Multimodal Program for Cancer Related Cachexia Prevention
|
N/A | |
| Completed |
NCT01222728 -
Using Positron Emission Tomography to Predict Intracranial Tumor Growth in Neurofibromatosis Type II Patients
|
||
| Recruiting |
NCT06004440 -
Real World Registry for Use of the Ion Endoluminal System
|
||
| Active, not recruiting |
NCT05636696 -
COMPANION: A Couple Intervention Targeting Cancer-related Fatigue
|
N/A | |
| Not yet recruiting |
NCT06035549 -
Resilience in East Asian Immigrants for Advance Care Planning Discussions
|
N/A | |
| Recruiting |
NCT06004466 -
Noninvasive Internal Jugular Venous Oximetry
|
||
| Completed |
NCT03190811 -
Anti-PD-1 Alone or Combined With Autologous DC-CIK Cell Therapy in Advanced Solid Tumors
|
Phase 1/Phase 2 |